Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer

Sponsor
Japan Multinational Trial Organization
Study ID
NCT00132054
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy, such as amrubicin and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of amrubicin when given together with irinotecan in treating patients with recurrent or relapsed extensive stage small cell lung cancer.

Key Dates

Start date
May 31, 2004
Status verified
Dec 2006
Primary completion
Dec 31, 2006
Completion
Nov 30, 2008

Study Design

Enrollment
30 participants (estimated)
Primary purpose
TREATMENT

Related Studies